Depression Treatment Market Size Worth USD 16.06 Billion by 2027 | Emergen Research

The global Depression Treatment Market is forecasted to be worth USD 16.06 Billion by 2027, according to a current analysis by Emergen Research. The Depression Treatment Market report further mentions that the market would register a CAGR of 3.9% from 2020 to 2027. Depression is a medical illness that involves both the physical and mental health of an individual and is characterized by feelings of sadness, loss of interest, change in appetite, low energy levels, among others.

The growing incidence of mental health and depression disorders is the primary driver for the depression treatment market. According to the World Health Organization, more than 264 million people of all ages suffer from depression globally. According to the National Institute of Mental Health (NIMH), in 2017, an estimated 16.2 million adults aged 18 or older in the U.S had at least one major depressive episode in the past year, which represented 6.7% of all adults in the U.S. The prevalence of depression is highest among adults aged 18-25 years (9.6%), followed by those aged 26-49 years (8.5%). Women are more likely than men to experience depression, with 8.5% of women and 5.3% of men experiencing a major depressive episode in the past year. Depression is one of the leading causes of disability and is a major contributor to the overall global burden of disease. Early diagnosis and treatment of depression can help reduce the burden of the disease.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/191

The lower cost of antidepressants and other drugs, the high prevalence of depression, and the availability of insurance are among the key factors driving the growth of this market. The rising awareness about mental health and its effects on people’s lives is also anticipated to fuel demand for depression treatments over the forecast period.

Some Key Highlights from the Report

• In October 2020, a global biotech company, ATAI Life Sciences, announced that it had acquired a small molecule development company, Gossamer Bio. The acquisition will bolster ATAI’s R&D capabilities in the field of psychiatry and help the company develop new treatments for depression.
• The antipsychotics treatment segment is expected to grow at a significant CAGR during the forecast period due to the high efficacy of antipsychotics drugs in the treatment of depression. Furthermore, the government initiatives to promote the use of antipsychotic drugs for the treatment of depression is also expected to fuel the growth of this segment over the forecast period.
• The antidepressant treatment segment is expected to grow at a significant CAGR over the forecast period due to the availability of a wide range of antidepressants drugs in the market. Moreover, the government initiatives to promote the use of antidepressants for the treatment of depression is also expected to fuel the growth of this segment over the forecast period. Antidepressants are commonly prescribed medications for treating depression. They work by correcting the chemical imbalance in the brain that causes depression. These drugs are effective in treating both mild and severe forms of depression.
• The SSRIs treatment segment is expected to grow at the highest CAGR during the forecast period due to the availability of a wide range of SSRIs drugs in the market. Moreover, the government initiatives to promote the use of SSRIs for the treatment of depression is also expected to fuel the growth of this segment over the forecast period. The selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressant drugs that are commonly used to treat depression. They work by increasing the levels of serotonin, a neurotransmitter that plays a key role in regulating mood, in the brain.
• The market in North America is expected to grow at the highest CAGR during the forecast period. The high growth in this region can be attributed to the increasing prevalence of depression, the availability of advanced treatment options, and the growing awareness about mental health disorders.
• Key participants include Pfizer, Inc., AstraZeneca, Plc, GlaxoSmithKline Plc, Eily, Lilly, and Company, Allergan Plc, Takeda Pharmaceutical Company Limited, Intellipharmaceutics International, Inc., Otsuka Holdings Co. Ltd., H.Lundbeck A/S, and Apotex, Inc., among others.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/depression-treatment-market

For the purpose of this report, Emergen Research has segmented into the global Depression Treatment Market on the basis of drug type, application, end-user, distribution channel, and region:

Drug Type Outlook (Revenue, USD Billion; 2017-2027)

• Antidepressants
  1. Selective Serotonin Reuptake Inhibitors (SSRIs)
  2. Selective Norepinephrine Reuptake Inhibitors (SNRIs)
  3. Serotonin Modulators
  4. Tricyclic & Tetracyclic Antidepressants
  5. Atypical Antidepressants
• Antipsychotics
• Others

Application Outlook (Revenue, USD Billion; 2017-2027)

• Major Depressive Disorder (MDD)
• Bipolar Disorder
• Postpartum Depression
• Premenstrual Dysphoric Disorder (PMDD)
• Dysthymic Disorder
• Seasonal Affective Disorder (SAD)
• Others

End-User Outlook (Revenue, USD Billion; 2017-2027)

• Hospitals
• NGOs
• Mental Health Centers
• Asylums
• Others

Distribution Channel Outlook (Revenue, USD Billion; 2017-2027)

• Hospitals Pharmacies
• Retail Pharmacies
• Online

Regional Outlook (Revenue, USD Million; 2019-2030)

• • North America
    1. U.S.
    2. Canada
    3. Mexico
  • Europe
    1. Germany
    2. France
    3. UK
    4. Italy
    5. Spain
    6. Benelux
    7. Rest of Europe
  • Asia Pacific
    1. China
    2. India
    3. Japan
    4. South Korea
    5. Rest of APAC
  • Latin America
    1. Brazil
    2. Rest of LATAM
  • Middle East & Africa
    1. Saudi Arabia
    2. UAE
    3. South Africa
    4. Turkey
    5. Rest of Middle East & Africa

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/191

Explore More Reports Emergen Research:

Smart Building Market

Photolithography equipment market

Animal Ultrasound Market

Aviation Fuel Systems Market

Optically Clear Adhesive Market

Small Caliber Ammunition Market

Metaverse market

Smart irrigation market

Ceramic fiber market

Acrylic resin market

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Emergen Research Media Citations: https://www.emergenresearch.com/media-citations

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Press Release Available @ https://www.emergenresearch.com/press-release/global-depression-treatment-market